Taiba Middle East announced that it has acquired exclusive distribution and marketing rights to Insmed’s Arikayce amikacin liposome inhalation suspension in Saudi Arabia, UAE, Kuwait, Oman, Qatar, and Bahrain, the six countries that make up the Gulf Cooperation Council.
In the US, Arikayce has been approved for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adult patients who have limited treatment options since September 2018, and it has been approved in Europe for the treatment of MAC lung infections in non-cystic fibrosis patients with limited treatment options since October 2020. Earlier this year, the Japanese Ministry of Health, Labour and Welfare also approved Arikayce for the treatment of NTM lung disease caused by MAC.
Taiba Group CEO Saif Al Hasani commented, “We are proud to collaborate with Insmed on the commercialization and distribution of Arikayce for the Gulf countries. Arikayce availability in the region addresses, for the first time, the needs of patients with refractory MAC lung disease. Doctors will have a new approach to help manage this difficult-to-treat condition for patients who have suffered with few, or no, treatment options. Taiba focuses on providing innovative therapies to patients in the Middle East region and supporting access to rare disease therapies; our collaboration with Insmed on Arikayce further enhances our orphan and rare disease distinguished portfolio.”
Insmed General Manager, Head of EMEA, Neil Hughes said, “We are pleased to partner with Taiba to provide access to Arikayce for appropriate patients in the Gulf Cooperation Council region. Taiba’s extensive experience in providing access to rare disease therapies in the Middle East makes it an ideal partner for Insmed as we expand our reach globally and serve patients with significant unmet needs.”
Read the Taiba press release.
